Siddi Medicine obtains the exclusive authorization of the new generation of CD47 antibody drug in Greater China

On March 31, 2021, Sidi Medicine, located in the Shanghai International Medical Park of Zhangjiang Science City, announced that it has obtained ImmuneOncia Therapeutics' new generation anti-CD47 monoclonal antibody IMC-002 tumor indication in Greater China (Mainland China, Hong Kong, Macau and Taiwan) The exclusive authorization for the development, production and commercialization of The company plans this year to the State Drug Administration submitted a clinical trial application (IND) Bureau (NMPA).

According to public information, Sidi Medicine was established in 2015.

According to the terms of the agreement, Sidi Medicine will pay a down payment of 8 million U.

IMC-002 is a new fully humanized IgG4 monoclonal antibody targeting CD47 .

CD47, also known as integrin-associated protein (IAP), belongs to the immunoglobulin superfamily and is one of the popular targets in the field of tumor immunotherapy .

According to the Medical Rubik's Cube Global Clinical Trial Database, there are 60 monoclonal antibodies against CD47 and CD47/SIRPα under research in the world.

In China, according to Insight database statistics, ten companies have deployed CD47 target products, including a number of research projects developed by companies such as Tianjing Biological, Cinda Biological, Hengrui Medicine, Kangfang Biological, and Hansi Biomedicine, among which , Cinda Bio's CD47 target product research and development progress is in a leading position.

In addition, as one of the popular targets, CD47 has attracted much attention.